HIGHLIGHTS
- who: Rachel Houten from the The National Institute for Health and Care Excellence (NICE) provides guidance to improve health and social care in and Implementation Group, part of the University of Liverpool, was commissioned to act as the Evidence Review Group have published the research work: Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, in the Journal: (JOURNAL)
- what: This article summarises the ERG`s review of the evidence submitted by the company and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.